Aligos TherapeuticsALGS -2.22%37 PS Ratio is 14.67 as of Jul. 11, 2026, which is 40% above its 10-year median of 10.51. GuruFocus rates ALGS with a GF Score™ of 37/100 and a GF Value™ of $2.78 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 930 Biotechnology companies, Aligos Therapeutics ranks worse than 59.68% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Aligos Therapeutics's share price is $6.63.
Aligos Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.45. Hence, Aligos Therapeutics's PS Ratio for today is 14.67.
The historical rank and industry rank for Aligos Therapeutics's PS Ratio or its related term are showing as below:
ALGS'
s PS Ratio Range Over the Past 10 Years
Min: 1.27 Med: 10.51 Max: 1381.58
Current: 14.65
During the past 8 years, Aligos Therapeutics's highest PS Ratio was 1381.58. The lowest was 1.27. And the median was 10.51.
ALGS's PS Ratio is ranked worse than 59.68% of 930
companies
in the Biotechnology industry
Industry Median: 9.515
vs ALGS: 14.65
During the past 8 years, Aligos Therapeutics's highest 3-Year average Revenue per Share Growth Rate was -38.70% per year. The lowest was -69.90% per year. And the median was -54.30% per year.
Back to Basics: PS Ratio
Aligos Therapeutics (NAS:ALGS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Aligos Therapeutics PS Ratio Related Terms
Aligos Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Aligos Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aligos Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aligos Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Aligos Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Aligos Therapeutics's Share Price of today is $6.63. Aligos Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.45.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Aligos Therapeutics (ALGS) has a PS Ratio of 14.67 as of Jul. 11, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Aligos Therapeutics and its competitors. This is 40% above median its historical median of 10.51. Over the past decade, Aligos Therapeutics' PS Ratio has ranged from 1.27 to 1,381.58. According to the industry distribution chart, Aligos Therapeutics ranks #555 out of 930 companies in the Biotechnology industry, placing it in the top 59.7%.
Is Aligos Therapeutics' PS Ratio too high?
Aligos Therapeutics' current PS Ratio of 14.67 is 40% above median its 10-year median of 10.51. Over the past 10 years, this metric has ranged from a low of 1.27 to a high of 1,381.58. The Biotechnology industry median PS Ratio is 9.52. Aligos Therapeutics' value of 14.67 is 54.2% above this industry median. Based on the distribution chart, Aligos Therapeutics ranks #555 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aligos Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' PS Ratio compare to SNTI and NTRB?
According to the Biotechnology industry distribution chart, Aligos Therapeutics ranks #555 out of 930 companies for PS Ratio. This places Aligos Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.52. Aligos Therapeutics' value of 14.67 is 54.2% above this benchmark. Historically, Aligos Therapeutics' own PS Ratio has ranged from 1.27 to 1,381.58 over the past decade. While the company's 10-year median is 10.51 vs. the industry median of 9.52, Aligos Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aligos Therapeutics's current PS Ratio of 14.67 is 54.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Aligos Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aligos Therapeutics's current PS Ratio is 14.67, which is 40% above median its own 10-year median of 10.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.78, compared to a current price of $6.63 — trading 138.5% above its estimated fair value. The current PS Ratio is 14.67, which is 40% above median its 10-year median of 10.51 and 54.2% above the Biotechnology industry median of 9.52. Aligos Therapeutics' overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current PS Ratio is 14.67 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aligos Therapeutics (ALGS) Overvalued in 2026?
Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued.
The current stock price of $6.63 is trading 138.5% above its estimated GF Value™ of $2.78.
GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.
Key valuation signals for ALGS:
PS Ratio: 14.67 (40% above median its 10-year median of 10.51)
GF Value™: $2.78 vs. price of $6.63 (138.5% above fair value)
Industry Position: 54.2% above the Biotechnology median (#555 of 930)
No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
37GF Score
Get the complete analysis for ALGS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALGS has been successfully added to your 
